doi:10.3969/j.issn.1673-8640.2017.12.012

Abstract

CLC Number:

R446.1

Figures/Tables 5

References 13

[1]	LORENZ M W,SCHAEFER C,STEINMETZ H,et al.Is carotid intima media thickness useful for individual prediction ofcardiovascular risk? Ten-year results from the carotid atherosclerosis progression study(CAPS)[J]. Eur Heart J,2010,31(16):2041-2048.
[2]	PARK H W,KIM W H,KIM K H,et al.Carotid plaque is associated with increased cardiac mortality in patients with coronary artery disease[J]. Int J Cardiol,2013,166(3):658-663.
[3]	NAQVI T Z,LEE M S.Carotid intima-media thickness and plaque in cardiovascular risk assessment[J]. JACC Cardiovasc Imaging,2014,7(10):1025-1038.
[4]	AMSTERDAM E A,WENGER N K,BRINDIS R G,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol,2014,64(24):e139-e228.
[5]	SELVIN E,STEFFES M W,ZHU H,et a1. Glycated hemoglobin,diabetes,and cardiovascular risk in nondiabetic adults[J]. N Engl J Med,2010,362(9):800-811.
[6]	American Diabetes Association.Diagnosis and classification of diabetes mellitus[J]. Diabetes Care,2010,33(Suppl 1):S62-S69.
[7]	TEMELKOVA-KURKTSCHIEV T S,KOEHLER C,HENKEL E,et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level[J]. Diabetes Care,2000,23(12):1830-1834.
[8]	BOBBERT T,MAI K,FISCHER-ROSINSKY A,et al.A1C is associated with intima-media thickness in individuals with normal glucose tolerance[J]. Diabetes Care,2010,33(1):203-204.
[9]	MCNEELY M J,MCCLELLAND R L,BILD D E,et al.The association between A1C and subclinical cardiovascular disease:the multi-ethnic study of atherosclerosis[J]. Diabetes Care,2009,32(9):1727-1733.
[10]	HUNG C S,LEE P C,LI H Y,et a1. Haemoglobin Alc is associated with carotid intima-media thickness in a Chinese population[J]. Clin Endocrinol(Oxf),201l,75(6):780-785.
[11]	孙婉婉,刘宇,王天歌,等. 糖调节受损人群糖化血红蛋白与颈动脉内中膜厚度的相关性研究[J]. 内科理论与实践,2012,7(3):180-184.
[12]	AHMED N.Advanced glycation endproducts-role in pathology of diabetic complications[J]. Diabetes Res Clin Pract,2005,67(1):3-21.
[13]	PEPPA M,URIBARRI J,VLASSARA H.The role of advanced glycation end products in the development of atherosclerosis[J]. Curr Diab Rep,2004,4(1):31-36.

组别	例数	年龄（岁）	性别		BMI	收缩压（kPa）	舒张压（kPa）
组别	例数	年龄（岁）	男性[例（%）]	女性[例（%）]	BMI	收缩压（kPa）	舒张压（kPa）
CIMT正常组	1 773	45.64±9.66	1 145（64.58）	628（35.42）	23.45±2.99	16.65±2.16	10.38±1.59
CIMT增厚组	240	52.58±9.62^*	196（81.66）^*	44（18.34）	24.02±2.94^*	17.51±2.24^*	10.91±1.52^*
斑块组	210	58.47±10.73^*#	160（76.19）^*	50（23.81）	24.16±2.90^*	18.09±2.94^*#	10.66±1.73^*#
统计值		197.05	36.09		8.27	49.22	17.05
P值		<0.01	<0.01		<0.01	<0.01	<0.01
组别	血糖（mmol/L）		HbA_1c （%）	TC （mmol/L）	TG （mmol/L）	HDL-C （mmol/L）	LDL-C （mmol/L）
CIMT正常组	4.93±0.99		5.43±0.66	5.12±0.91	1.85±1.56	1.46±0.36	2.89±0.74
CIMT增厚组	5.08±0.90^*		5.59±0.66^*	5.26±0.94^*	2.02±1.46	1.44±0.36	2.96±0.82
斑块组	5.50±1.59^*#		5.88±0.94^*#	5.24±1.09	1.99±1.49	1.43±0.36	2.99±0.91
统计值	28.99		42.13	3.56	1.83	1.43	1.86
P值	<0.01		<0.01	0.029	0.16	0.24	0.16

组别	例数	年龄（岁）	性别		BMI	收缩压（kPa）	舒张压（kPa）
组别	例数	年龄（岁）	男性[例（%）]	女性[例（%）]	BMI	收缩压（kPa）	舒张压（kPa）
CIMT正常组	1 773	45.64±9.66	1 145（64.58）	628（35.42）	23.45±2.99	16.65±2.16	10.38±1.59
CIMT增厚组	240	52.58±9.62^*	196（81.66）^*	44（18.34）	24.02±2.94^*	17.51±2.24^*	10.91±1.52^*
斑块组	210	58.47±10.73^*#	160（76.19）^*	50（23.81）	24.16±2.90^*	18.09±2.94^*#	10.66±1.73^*#
统计值		197.05	36.09		8.27	49.22	17.05
P值		<0.01	<0.01		<0.01	<0.01	<0.01
组别	血糖（mmol/L）		HbA_1c （%）	TC （mmol/L）	TG （mmol/L）	HDL-C （mmol/L）	LDL-C （mmol/L）
CIMT正常组	4.93±0.99		5.43±0.66	5.12±0.91	1.85±1.56	1.46±0.36	2.89±0.74
CIMT增厚组	5.08±0.90^*		5.59±0.66^*	5.26±0.94^*	2.02±1.46	1.44±0.36	2.96±0.82
斑块组	5.50±1.59^*#		5.88±0.94^*#	5.24±1.09	1.99±1.49	1.43±0.36	2.99±0.91
统计值	28.99		42.13	3.56	1.83	1.43	1.86
P值	<0.01		<0.01	0.029	0.16	0.24	0.16

指标	B值	标准误	Wald值	Sig值	Exp（B）（95%CI）
TC	0.13	0.06	4.23	0.04	1.14（1.01~1.30）
HbA_1c	0.21	0.08	6.40	0.01	1.24（1.05~1.46）
年龄	0.10	0.01	203.76	<0.01	1.10（1.09~1.12）
性别	0.79	0.14	29.92	<0.00	2.21（1.66~2.93）
舒张压	0.01	0.01	4.39	0.04	1.01（1.00~1.02）

指标	B值	标准误	Wald值	Sig值	Exp（B）（95%CI）
TC	0.13	0.06	4.23	0.04	1.14（1.01~1.30）
HbA_1c	0.21	0.08	6.40	0.01	1.24（1.05~1.46）
年龄	0.10	0.01	203.76	<0.01	1.10（1.09~1.12）
性别	0.79	0.14	29.92	<0.00	2.21（1.66~2.93）
舒张压	0.01	0.01	4.39	0.04	1.01（1.00~1.02）

指标	B值	标准误	Wald值	Sig值	Exp（B）（95%CI）
TC	0.13	0.08	3.03	0.08	1.14（0.98~1.33）
年龄	0.07	0.01	90.55	<0.01	1.07（1.06~1.09）
性别	0.87	0.18	22.50	<0.01	2.39（1.67~3.42）
舒张压	0.02	0.01	7.81	0.01	1.02（1.01~1.03）

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 13

Related Articles 15

Recommended Articles

Metrics

指标	B值	标准误	Wald值	Sig值	Exp（B）（95%CI）
TC	0.16	0.08	3.84	0.05	1.17（1.00~1.38）
HbA_1c	0.25	0.09	8.10	<0.01	1.29（1.08~1.53）
年龄	0.12	0.01	179.87	<0.01	1.12（1.11~1.14）
性别	0.76	0.19	16.11	<0.01	2.15（1.48~3.12）

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.